Important results from the project
The project was implemented according to plan and all objectives were achieved. A technical batch was produced as final step before GMP manufacturing and processes for production, coupling and analysis were verified. The results have strengthened Abera´s vaccine technology platform and analysis methods are transferable to other vaccine candidates. The lessons learned will streamline upcoming projects and create the conditions for clinical studies on our pneumococcal vaccine candidate in 2026.
Expected long term effects
The project lays the foundation for a new nasal pneumococcal vaccine that can protect against both disease and transmission, thereby saving lives, especially among children and the elderly. The results strengthen Abera´s platform for pandemic preparedness and enable rapid development of new vaccines, for example against influenza and future viral outbreaks. A cost-effective, stable and nasally administered vaccine technology can contribute to global equitable access to vaccines.
Approach and implementation
The project followed the plan set at the start, with a focus on process development, verification of analytical methods and production of a technical batch for GMP production. The collaboration with the contract manufacturer worked well, although some delays occurred due to a lack of available production slots. The project has otherwise run according to plan and delivered planned results in the right quality.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
